Sign In  |  Register  |  About Menlo Park  |  Contact Us

Menlo Park, CA
September 01, 2020 1:28pm
7-Day Forecast | Traffic

  • Search Hotels in Menlo Park

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

748.01 -1.91 (-0.25%)
Official Closing Price Updated: 7:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Move Over Ozempic! 3 New GLP-1 Drugs and Products Coming Soon.
The search for the next GLP-1 drugs that will be blockbuster winners during the next market cycle is on, and here are three contenders. 
Via InvestorPlace
Surprise: Eli Lilly Is Racing Toward Yet Another Blockbuster
This winner can't stop winning. 
Via The Motley Fool
Australia Bans Replica Versions Of Popular Weight-Loss Drugs From Novo Nordisk, Eli Lilly On Safety Concerns
Compounding weight loss drugs, which are similar to brand-name medications such as Ozempic and Mounjaro, will be banned in Australia. 
Via Benzinga
The 500 Top Stocks to Buy in May, According to AI
MarketMaster AI tells us that the top stocks to buy in May represent high-quality companies with strong fundamentals. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Retire Rich: 3 Game-Changing Stocks to Own for the Next 10 Years
Here are three game-changing retirement stocks to own for the long-term, for those looking to create meaningful long-term wealth. 
Via InvestorPlace
Topics Retirement
Exposures Pension
Here's How Much $100 Invested In Eli Lilly and Co 5 Years Ago Would Be Worth Today
Via Benzinga
Evaluating Eli Lilly and Co Against Peers In Pharmaceuticals Industry
Via Benzinga
This Biotech Stock Is Poised For 80% Upside With Breakthrough In Obesity Drug Market, Says JPMorgan
The Structure Therapeutics stock has been identified as a potential winner in the obesity drug market. JPMorgan has given the stock a significant upside potential. 
Via Benzinga
Tesla's Fall From Grace: Down 55% From Its Peak
There was a time when Tesla was the Nvidia of its day. Its stock did nothing but go up, and its earnings calls were intensely anticipated. For a full 30 months now, Tesla is down 55% from its peak. 
Via Talk Markets
EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic
Roundhill CEO Dave Mazza says investors "can't just buy a basket of big pharma names or a broad-based biotech ETF and call it a day." 
Via Benzinga
Topics ETFs
3 Growth Stocks That Could Be Millionaire-Makers: May Edition
Investors wanting to get rich should consider a long-term holding in these stocks, each of which has risen exponentially in the last year. 
Via InvestorPlace
Weight Loss Drugs Like Wegvoy and Zepbound Users - Nestlé Launches $5 Pizza For You
Nestlé SA launches Vital Pursuit, a new food line tailored for GLP-1 weight loss medication users, featuring protein, fiber, and essential nutrients. Available Q4 nationwide. 
Via Benzinga
If You'd Invested $10,000 in Eli Lilly Stock 5 Years Ago, Here's How Much You'd Have Today
Have Eli Lilly's successes translated into stock performance? 
Via The Motley Fool
7 Reliable Blue-Chip Stocks That Cannot Miss
These reliable blue-chip stocks to own are the closest thing to slam dunk investments that exist. Discover why you should buy them now. 
Via InvestorPlace
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1... 
Via Benzinga
3 S&P 500 Stocks to Buy in May Before They Rocket Higher
These three stocks sit on the precipice of huge, long-term gains, making them among the best to grab now before they soar. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
HIMS stock is catching a bid after Hims & Hers announced that it would begin providing access to GLP-1 weight-loss injections. 
Via InvestorPlace
Magnificent Seven? Just Two Members Meet This Earnings Criteria
These megacaps meet triple-25% growth standards. 
Via Investor's Business Daily
Is Amgen a Threat to Eli Lilly in This Billion-Dollar Market?
Eli Lilly's biggest growth drivers today are its weight loss drugs. 
Via The Motley Fool
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market. 
Via Benzinga
Topics ETFs
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason. 
Via InvestorPlace
Rally Rockets: 3 Stocks Benefitting From the Market’s Unstoppable Surge
Don't miss out on profit potential of these stocks to buy. Explore three top stocks poised to unlock gains in a surging market. 
Via InvestorPlace
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries 
Via News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug? 
Via The Motley Fool
3 Stocks To Buy Following Positive Earnings Results
Total earnings for the S&P 500 members that have reported Q1 results are up +4.8% from the same period last year on +4.1% higher revenues. The earnings growth pace reflects an acceleration relative to... 
Via Talk Markets
Topics Stocks
Exposures US Equities
Eli Lilly's Weekly Insulin Dose On Par With Commonly Used Daily Doses, Phase 3 Studies Show
Eli Lilly phase 3 trials reveal once-weekly insulin efsitora as a non-inferior alternative to daily basal insulins for type 2 diabetes. 
Via Benzinga
The Dividend Investor’s Playbook: 3 Stocks for Consistent Cash Flow in 2024
Dive into dividend stocks to buy, featuring Walmart's robust earnings and Eli Lilly's advances in pharmaceuticals and WMT's stock split. 
Via InvestorPlace
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
These 2 No-Brainer Growth Stocks Are Breaking New Ground
The future keeps getting brighter for these companies. 
Via The Motley Fool
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
< Previous 1 2
...
25 26 27 28 29 30 31 32 33
...
99 100 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 MenloPark.com & California Media Partners, LLC. All rights reserved.